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Inosine monophosphate dehydrogenase (IMPDH), a rate-limit-
ing enzyme in the de novo synthesis of guanine nucleotides, is a
major therapeutic target. A prototypic uncompetitive inhibitor of
IMPDH, mycophenolic acid (MPA), is the active form of mycophe-
nolate mofeteil (CellCept), a widely used immunosuppressive
drug.We have found thatMPA interacts with intracellular IMPDH
in vivo to alter its mobility on SDS-polyacrylamide gels. MPA also
induces a striking conformational change in IMPDH protein in
intact cells, resulting in the formation of annular aggregates of pro-
tein with concomitant inhibition of IMPDH activity. These aggre-
gates are not associatedwith any known intracellular organelles and
are reversible by incubating cells with guanosine, which repletes
intracellular GTP, or with GTPS. GTP also restores IMPDH activ-
ity. Treatment of highly purified IMPDH with MPA also results in
the formation of large aggregates of protein, a process that is both
prevented and reversed by the addition of GTP. Finally, GTP binds
to IMPDH at physiologic concentrations, induces the formation of
linear arrays of tetrameric protein, and prevents the aggregation of
protein induced by MPA. We conclude that intracellular GTP acts
as an antagonist to MPA by directly binding to IMPDH and revers-
ing the conformational changes in the protein.
Inosinemonophosphate dehydrogenase (IMPDH)3 catalyzes the first
step in the de novo synthetic pathway for the formation of guanine
nucleotides by converting IMP to xanthosine 5-monophosphate
(XMP) with the concomitant reduction of NAD. As the rate-limiting
step in this pathway, the enzyme has been identified as an important
regulator of cell proliferation. Inhibitors of IMPDH are in clinical use as
immunosuppressive agents and have potential utility in the treatment of
neoplastic and viral diseases (1–5). Two isoforms of IMPDH have been
identified, the type I form that is expressed at lower levels in all cell types
and the type II form that is more highly expressed in proliferating and
transformed cell types (6, 7). These enzymes have 84% amino acid iden-
tity, and both are catalytically active as tetramers of 55-kDa subunits
with similar, although not identical, kinetic profiles.
Studies on the regulation of IMPDH activity have demonstrated
strong transcriptional up-regulation of the type II mRNA in response to
mitogenic stimuli in peripheral blood lymphocytes and in response to
enzyme inhibition and guanine nucleotide depletion in a number of cell
types (8, 9). Until recently, very little attention has been paid to the role
of protein structure in regulating its activity. The finding thatmutations
within the IMPDH type I coding region are associated with a familial
form of retinitis pigmentosa (10) has initiated renewed interest in the
structure of IMPDH, first crystallized in 1996 (11). These mutations
occur within a region of the protein termed the cystathione -synthase
domain that has recently been shown to bind oligonucleotides up to
100-base pair in length (12). In addition, this domain binds ATP, result-
ing in allosteric activation of the enzyme (13). It has thus been postu-
lated that IMPDHmay act as an energy sensor in cells and have a more
complex role in cellular physiology than previously imagined.
In investigating the potential of IMPDH inhibitors as antineoplastic
drugs, we have discovered that these inhibitors inducemacroaggregates
of IMPDH protein that are reversible by the addition of GTP and to a
lesser extent byATP.More spectacularly,most aggregates take the form
of ring structures in the cytoplasm of intact normal and neoplastic cells
that regress with the repletion of intracellular guanine nucleotides. The
unique nature of this protein self-associationmay account in part for the
effects of IMPDH inhibitors and suggest that intracellular levels of GTP
may regulate the interaction of IMPDH with small molecule inhibitors.
EXPERIMENTAL PROCEDURES
Cell Culture and Treatment Conditions—The human breast cancer
cell line MCF7 was cultured in Dulbecco’s modified Eagle’s medium
supplemented with 10% heat-inactivated fetal bovine serum and 100
g/ml penicillin and streptomycin. The human acute lymphoblastic
leukemia cell line CEM and hypoxanthine-guanine phosphoribosyl
transferase (HGPRT)-deficient hybridoma K6H6/B5 cells (ATCC,
Manassas, VA) were cultured in RPMI 1640 medium with the same
supplements. HGPRT-deficient CEM cells were maintained in 5 g/ml
6-thioguanine in RPMI 1640 medium with supplements.
Mycophenolic acid (Sigma) was solubilized in ethanol and used at a
final concentration of 2 M. Equal volumes of ethanol were added to all
untreated controls. Guanosinewas added to a final concentration of 100
M. GTP and non-hydrolyzable GTPS (Sigma) were used at 1 mM.
Leukemic Cell Isolation and Western Blots—Peripheral blood sam-
ples were obtained from a patient with chronic myelogenous leukemia
treated with CellCept, an ester pro-drug of MPA, and a normal volun-
teer.Mononuclear cells were separated usingHistopaque-1077 (Sigma).
The cells were lysed by three freeze-thaw cycles in an extraction buffer
containing 200mMTris-HCl, pH 7.5, 200mMNaCl, 10% glycerol, 2 mM
dithiothreitol, 5 mM MgCl2, 1 mM EGTA, 2 g/ml leupeptin and
pepstatin, and 0.1 mM phenylmethylsulfonyl fluoride. Total lysates
(10 g) were run on a 15% SDS-polyacrylamide gel. TheWestern blot
was probed using a polyclonal antibody kindly provided by Vertex
(Cambridge, MA).
IMPDH Activity Assay—The enzymatic activity of IMPDH was
measured by the increase in absorbance at 290 nm (formation of XMP)
* This work was supported in part by National Institutes of Health Grant RO-1 CA64192.
Electron microscopy studies were supported by National Institutes of Health Grants
CA16086 and GM31819 (to J. D. G.). The costs of publication of this article were
defrayed in part by the payment of page charges. This article must therefore be
hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to
indicate this fact.
1 Supported as a Rothrock Thomas fellow.
2 To whom correspondence should be addressed. Tel.: 650-725-9621; Fax: 919-966-8212;
E-mail: mitchell@med.unc.edu.
3 The abbreviations used are: IMPDH, inosine monophosphate dehydrogenase; HGPRT,
hypoxanthine-guanine phosphoribosyl transferase; MPA, mycophenolic acid; BSA,
bovine serum albumin; XMP, xanthosine 5-monophosphate.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 281, NO. 1, pp. 206 –212, January 6, 2006
© 2006 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.
206 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 281 • NUMBER 1 • JANUARY 6, 2006
This is an Open Access article under the CC BY license.
in crude cell extracts or at 340 nm (formation of NADH) for purified
IMPDH at 37 °C. The assay buffer was prewarmed to 37 °C and con-
tained 100 mM Tris/HCl, pH 8.0, 100 mM KCl, 50 g/ml BSA, 1 mM
dithiothreitol, 2 mM EDTA, 5 mMMgCl2, 200 M IMP, 200 MNAD.
The activities from 40 l of whole cell extracts or 5 g of purified
IMPDH were recorded over 10 min after adding 1 ml of assay buffer by
a temperature-controlled UV-visible recording spectrophotometer
UV160U (Shimadzu Co., Kyoto, Japan). The amount of protein was
determined by Bradford protein assay, and the activity is expressed as
nmol/min/mg protein.
Immunohistochemical and Electron Micrograph Analysis of IMPDH—
MCF7 cells were cultured on coverslips in 12-well plates in the absence or
presence of 2 MMPA and the indicated additives. Cells were fixed for 15
min in 1 ml of 4% paraformaldehyde (ElectronMicroscopy Sciences, Hat-
field, PA) followed by treatmentwith 0.2%TritonX-100 for 5min.After 30
minof blocking, the cellswere incubatedwith 100l of rabbit anti-IMPDH
antibody diluted 1:300 in 50% blocking solution (2% fetal bovine serum, 2%
BSA, 2% normal goat and rabbit serums in phosphate-buffered saline) for
1 h at room temperature. The cells were then incubated with fluorescein
isothiocyanate-labeled goat anti-rabbit conjugates diluted 1:300 in 50%
blocking solution for 1 h, washed three times with phosphate-buffered
saline, and mounted with Vectorshield (Vector, Peterborough, UK) for
fluorescent and confocal microscopy.
For immunonanogold staining and electron microscopy, cells were
fixed with 1% glutaraldehyde and blocked with 1% BSA in phosphate-
buffered saline for 30 min. The IMPDH antibody in 1% BSA was incu-
bated with cells for 1 h, and the cells were washed and incubated with
1:200 NANOGOLD reagent (Nanoprobe Inc., Yaphank, NY) for 1 h at
room temperature. Cells were post-fixed with 1% glutaraldehyde. The
nanogold particles were then silver enhanced using a HQ Silver
Enhancement kit (Nanoprobe Inc.) according to the manufacturer’s
instruction. The ultrathin sections were stained with lead-citrate solu-
tion and were examined with a Philips CM12 transmission electron
microscope.
Gel Filtration of Proteins with FPLC—MCF7 cells cultured with 2 M
MPA for 6 h were harvested and briefly sonicated on ice in phosphate-
buffered saline containing 100 mM KCl, 1 mM dithiothreitol, 0.1%
Tween 20, and protease inhibitor mixture. The whole cell extracts were
clarified by centrifugation at 14,000 rpm for 20 min and applied to a
Sephacryl S-500 column connected to an FPLC system (AmershamBio-
sciences). Fractions were collected at a flow rate of 12 ml/h. Equal vol-
umes of proteins from each fraction were resolved by SDS-PAGE and
immunoblotted using anti-IMPDH-specific antibody. The relative pro-
tein levels of IMPDH were quantitated by a densitometer. Protein
standards (Sigma) were applied to the same column to generate a stand-
ard curve, from which the molecular masses for IMPDH and its aggre-
gates were calculated.
Recombinant Human IMPDH Purification and Treatment in Vitro—
To facilitate purification, the type II IMPDH cDNAwas cloned into the
pET-24C vector and transformed into Escherichia coli BL21 (DE3).
After induction with isopropyl thiogalactoside, the cell pellets were
resuspended in 1 binding buffer (Invitrogen) containing 5 mM dithio-
threitol, 1 mg/ml lysozyme, and EDTA-free protease inhibitor mixture.
Following sonication on ice and centrifugation at 25,000  g for 20 min
at 4 °C, the His-tagged IMPDH II proteins were purified on a nickel-
nitrilotriacetic acid column (Invitrogen). Fractions were collected using
a 50–200 mM imidazole gradient elution and were dialyzed with buffer
containing 50mMHEPES, pH 7.9, and 100mMKCl. Glycerol was added
to a final concentration of 20%, and the samples were stored at 20 °C.
For in vitro treatment, the purified IMPDH was further diluted to a
final concentration of 0.1 mg/ml, and 2 M MPA was added for 15 min
at room temperature. IMPDH proteins were spread on polylysine-
coated glass slides, stained using the immunohistochemical staining
procedure, and visualized by fluorescent microscopy at a magnification
of1000. Purified IMPDHwas also prepared for electronmicroscopy at
a final concentration of 50g/ml inHEPES buffer. After treatment with
nucleotides, MPA, or the combination, each sample was mounted on
glow charged thin carbon foils and stained with 2% uranyl acetate (14).
Micrographs were taken on a Philips CM12 electron microscope at 80
kV and a magnification of 45,000.
GTP Binding Assay—Binding of GTP to purified IMPDH was deter-
mined with a rapid filtration technique (13, 15). 1.0 M [-32P]GTPwas
mixed with increasing concentrations of cold GTP and incubated with
0.25 M (55 g/ml) IMPDH for 10 min at room temperature in 20 l of
reaction buffer containing 50mMTris-HCl, pH 8.0, 150mMKCl, 2.5M
BSA. Nonspecific control values were obtained under the same condi-
tions substituting BSA for IMPDH. 10 l of the reaction mixture were
loaded on a Millipore MF filter membrane (Millipore Corp.) rapidly
under vacuum and washed with 1 ml of ice-cold reaction buffer. Radio-
activity on the filters was measured by scintillation counting, and data
were plotted using SigmaPlot (SYSTAT).
RESULTS
Effect of MPA on IMPDH Protein—To study the direct effect of MPA
on IMPDH protein, we performed Western blot analysis of IMPDH
following MPA treatment. In MCF7 cells, a distinct decrease in the
mobility of IMPDH occurred within 5 min of MPA addition (Fig. 1A,
lane 3). The addition of guanosine, which restores guanine nucleotide
pools through the HGPRT salvage pathway, completely prevented this
band shift (Fig. 1A, lane 2). Approximately 50% of the protein migrated
more slowly, and the amount of protein shifted did not change with
increased time of incubationwith drug (Fig. 1A, lanes 4 and 5). A similar
shift has previously been reported for the yeast protein (16). Impor-
tantly, this shift was also observed for human IMPDHobtained from the
mononuclear cells of a patient treated with immunosuppressive doses
of CellCept, an ester pro-drug of MPA (Fig. 1B). The addition of
guanosine with MPA completely prevented the shift, whereas
guanosine treatment for the last 10 min slightly reduced the shift (Fig.
1C, lanes 3 and 4). The shifted band disappeared after withdrawal of
MPA (Fig. 1C, lane 5), reflecting the rapid metabolism of the bound
MPAby glucuronidation (17, 18). IMPDHactivity inMCF7 cells treated
with 2 M MPA for 24 h was decreased by 50% (Fig. 1D); this inhibi-
tion was completely reversed by the addition of guanosine for 60 min.
The changes in activity of IMPDH following MPA treatment correlate
with the amount of protein shifted on Western blots.
Aggregation of IMPDH Protein by MPA Treatment in Intact Cells—
We then examined the effect of MPA treatment on intracellular
IMPDH distribution by immunofluorescent staining. As shown in Fig.
2A, IMPDH is located diffusely in the cytosolic compartment in
untreated cells. Within 30 min of MPA treatment, IMPDH protein
started to formelongated structures.Within 24 h,we observed a striking
aggregation of the protein into perinuclear linear arrays more than 10
microns in length and subsequently into clearly defined annular config-
urations. This aggregation was seen in all cell lines examined, including
a number of leukemic and solid tumor cell lines, as well as in normal
peripheral blood lymphocytes. Using laser-powered confocal micros-
copy, we examined the shape of the aggregates in greater detail. As
shown in Fig. 2B, there was a marked predominance of ring formations.
Finally, we examined the structures using high resolution electron
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microscopy with immunonanogold staining of IMPDH in MCF7 cells
(Fig. 2C). After silver enhancement, the nanogold staining again dem-
onstrated IMPDH organized into large linear or circular arrays in the
cytoplasm. Of particular note is the fact that IMPDH is not associated
with any organelles or other defined intracellular structures by this high
resolution technique. In other studies, we did not find co-localization of
mitochondria, Golgi apparatus, endoplasmic reticulum, lipid bodies, or
cytokeratins with IMPDH by light microscopy (data not shown). In
addition, extensive co-immunoprecipitation experiments and tandem
affinity purification using tagged IMPDH did not demonstrate any
interacting protein other than endogenous IMPDH.
Reversal of IMPDH Aggregates by GTP—We then tested whether
guanosine reverses IMPDH aggregation by repleting guanine nucleo-
tide pools. MPA-induced IMPDH aggregates are reversed within 1 h by
adding 100 M guanosine to MCF7 cells cultured for 24 h in the pres-
ence of 2 M MPA (Fig. 3C). In data not shown, the addition of equiv-
alent concentrations of guanine, GMP,GDP, orGTPwere equally effec-
tive in reversing aggregation, whereas the addition of NAD, PRPP,
xanthine, hypoxanthine, adenosine, AMP, ADP, or ATP had no effect in
either MCF7 or CEM cells. We then asked whether the intracellular
HGPRT salvage pathway that converts guanine to GMP is necessary for
this effect. Guanosine is metabolized to guanine by the enzyme purine
nucleoside phosphorylase that is present in fetal bovine serum. The use
of HGPRT-deficient cells enabled us to determine whether either
guanosine or guanine had a direct effect on IMPDH aggregation or
whether they were acting through conversion into guanine nucleotides.
As shown in Fig. 3,A andB, guanosinewas unable to reverse the IMPDH
aggregates in HGPRT-deficient CEM and K6H6/B5 cells. However, the
addition of 1 mM GTP resulted in complete dispersal. This result is
surprising in that there is no well defined mechanism for the transport
of GTP directly from the extracellular to the intracellular compartment.
Therefore, these results were confirmed by adding GTPS, a non-hy-
drolyzable GTP analog, to MPA-treated MCF7 cells. The aggregates
dispersed, with the subsequent appearance of IMPDH in nucleoli and
diffusely within the cytoplasm within 60 min (Fig. 3C). Subsequent
experiments using [35S]GTPS confirmed that the nucleotide is able to
get across the MCF7 plasma membrane in a time- and dose-dependent
manner (data not shown). These results confirm that guanosine
reverses the MPA-induced IMPDH aggregates through salvage to gua-
nine nucleotides and that GTP is the direct effector. The structural
changes in IMPDH correlate with changes of activity. The50% reduc-
tion in activity induced byMPAwas completely reversed by the addition
of 1 mM GTPS to cells for 1 h (Fig. 3D). These data indicate that
FIGURE 1. Effects of IMPDH inhibitors on IMPDH and reversal by guanosine. A, West-
ern blot of MCF7 cell lysate after treatment with ethanol (lane 1), 2 M MPA plus 100 M
guanosine for 24 h (lane 2), or MPA for 5 min (lane 3), 2 h (lane 4), or 24 h (lane 5). IMPDH
type I (I) and IMPDH type II (II) are indicated. The arrow shows the shifted XMP-IMPDH
intermediate. B, mononuclear cells obtained from a normal volunteer (lane 1) and from a
patient treated with CellCept (lane 2). C, lysate from MCF7 cells untreated (lane 1) or
treated with MPA in the absence (lane 2) or presence (lanes 3 and 4) of 100 M guanosine.
Guanosine was added for the entire 60-min incubation period (lane 3) or for the final 10
min (lane 4). In lane 5, after 1 h of MPA treatment, cells were washed twice in medium and
incubated for an additional 60 min in the absence of drug. D, effect of MPA and
guanosine on IMPDH activity. MCF7 cells were incubated in the presence of 2 M MPA
(M) for 24 h. 100 M guanosine (G) was added for the final 30, 60, or 90 min. The cells were
then processed and assayed for IMPDH activity, as indicated under “Experimental Pro-
cedures.” Data are shown as the mean  S.E. of at least three determinations.
FIGURE 2. Effects of MPA on IMPDH aggregation and localization in intact cells. A,
immunofluorescent staining of intracellular IMPDH in MCF7 cells treated with 2 M MPA
for 30 min, 2 h, or 24 h. B, immunofluorescent staining of IMPDH after 24 h of MPA
treatment in MCF7 cells. Visualization with confocal microscopy was performed at a
magnification of 630. C, electron micrographs of MCF7 cells treated with MPA for 24 h.
Cells were stained with IMPDH-specific antibody and visualized with a secondary anti-
body conjugated with nanogold particles, as outlined under “Experimental Procedures.”
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increasing the intracellular GTP level overcomes the inhibition of
IMPDH induced by MPA.
IMPDH Aggregation Induced by MPA—To further define IMPDH
aggregation, the distribution of IMPDH in control or MPA-treated cell
extracts was examined using a Sephacryl S-500 size exclusion column
(Fig. 4A). Treatment of MCF7 cells with MPA for 6 h resulted in an
increase in the size of the IMPDH complex, as detected byWestern blot
of IMPDHmonomers, from a peak of 400 kDa to a peak of 600 kDawith
sizes ranging upwards of 2,000 kDa and extending into the void volume.
These data support the view that MPA promotes self aggregation of
IMPDH protein and that the higher molecular mass multimers are in
equilibrium (11, 19). Further support for this concept comes from stud-
ies on purified recombinant IMPDH type II. His-tagged IMPDH II
expressed in E. coli was purified to homogeneity. The protein was
treated with MPA, spread on polylysine-coated glass slides, and visual-
ized using standard immunofluorescence microscopy (Fig. 4B). Treat-
ment with MPA results in the formation of large aggregates with a
tendency to annular formation, although without the same level of def-
inition found in intact cells. These data demonstrate that MPA causes
self aggregation of IMPDH in the absence of other proteins or cellular
elements, most likely through conformational change (20).
Effect of GTP on IMPDH in Vitro—To examine the molecular
sequelae of both MPA- and GTP-induced changes on the purified pro-
tein, we performed uranyl acetate negative staining of protein followed
by electron microscopic examination (Fig. 5). This technique allows
visualization of IMPDHhomotetramers that are 14.6 0.9 nm (n 10)
in diameter. Protein treated only with ethanol exists predominantly as
single or ditetrameric units (panel A). MPA treatment for 15 min
resulted in the formation of large aggregates of the tetramer ranging in
size from 0.1 to 1 m in diameter (panel D). These aggregates are
stable in solution over time at room temperature. The addition of 1 mM
GTP alone to IMPDH protein in solution resulted in the formation of
linear arrays consisting of IMPDH tetramers (panel B). GTP reversed
the IMPDH aggregates formed as a consequence of MPA exposure
(panel E), again resulting in linear arrays. ATP, an allosteric activator of
IMPDH (13), also increased the formation of linear IMPDH chains
(panel C) and reduced the size of MPA-induced aggregates (panel F),
although neither effect was as pronounced as that caused by GTP. Both
GTP and ATP at 1–2 mM concentrations increased the activity of puri-
fied IMPDH by 20% (data not shown). Neither CTP nor UTP had any
effect on IMPDH alone or in the presence of MPA (not shown). MPA
treatment did not induce protein aggregation after preincubation with
GTP or ATP, but did with CTP or UTP (data not shown). These results
are summarized in Fig. 6.
IMPDH Binding of GTP—Although it has recently been demon-
strated that the cystathione -synthase domains of IMPDH can bind
FIGURE 3. Effects of guanosine and GTP on
IMPDH aggregation and activity in cells.
HGPRT CEM (A) or HGPRT K6H6/B5 (B) cells
were treated with MPA for 16 h. Guanosine (100
M) or GTP (1 mM) was added for the final 2 h of
culture. C, MCF7 (HGPRT) cells were treated with
2 M MPA for 24 h and with guanosine (100 M) or
non-hydrolyzable GTPS (1 mM) for the last 60 min.
D, IMPDH activity in untreated MCF7 cells for 24 h
(1), cells treated for 24 h with 2 M MPA alone (2)
or with 24-h MPA and GTPs for the final 1 h (3).
Data represent the mean  S.E. of three
determinations.
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ATP (13), GTP binding has not been demonstrated. Fig. 7 shows that
GTP binds to purified IMPDH protein, albeit with low affinity. Data
were fitted to a four-parameter logistic curve using SigmaPlot. The
apparent Kd is 72.9  8.1 M, which is within the physiologically rele-
vant range. This binding also displays positive cooperativity, with a Hill
slope of 1.7.
DISCUSSION
IMPDH has long been considered to be an important pharmacologic
target, and a number of inhibitors have been developed and used in
preclinical studies (21, 22). Of these, three are inwidespread clinical use.
Ribavirin, a broad spectrum antiviral agent used in the treatment of
Hepatitis C in combination with interferon-, is a relatively weak
IMPDH inhibitor (23). Mizoribine (Bredinin) and Mycophenolate
mofeteil (CellCept) are used as immunosuppressive agents in the setting
of organ transplantation, graft-versus-host disease, and vasculitis in
Japan and the United States, respectively (24). Given the clinical impor-
tance of IMPDH as a drug target, the enzyme has been crystallized from
a number of species and the structural basis of its inhibition has been
examined in detail as the basis for new drug design (11, 25, 26).
Human IMPDH is a tetramer of 55-kDa subunit consisting of /
barrels, with the active site located at themonomer-monomer interface.
The catalytic site is an/ barrel of400 residues. The substrate (IMP)
and cofactor (NAD) bind in a continuous cleft on the C-terminal face
of each barrel (25). The oxidation of IMP to XMP proceeds through a
covalent mechanism involving an active site cysteine residue. The
uncompetitive inhibitorMPA binds directly at the NAD site and traps
the XMP as a covalent intermediate in an open configuration of the
enzyme. Mizoribine, in contrast, must first be phosphorylated to its
monophosphate form and then binds at the substrate binding site,
inducing a closed conformation of the enzyme that does not trap XMP
(26).
We have shown that MPA induces a shift in IMPDH mobility in cell
lines treated with the drug and that this shift is both prevented and
reversed by the addition of guanosine to cell cultures, as well as by
removal of the MPA from the medium. Because a similar shift occurs
when the purified protein is incubated with drug in the presence of IMP
and NAD but is not found in cell lysates following mizoribine treat-
ment (data not shown), we suggest that it results from the enzyme-XMP
FIGURE 4. Effect of MPA in inducing aggregation of IMPDH. A, gel filtration of MCF7
cell lysate obtained from cells treated in the absence or presence of MPA for 6 h. Relative
IMPDH levels were examined by Western blot followed by densitometry of the 55-kDa
subunit band. B, immunostaining of purified IMPDH protein untreated or treated with 2
M MPA for 10 min. Protein was spread on polylysine-coated slides and visualized by
fluorescent microscopy at a magnification of 1000.
FIGURE 5. Electron micrographs of purified IMPDH protein treated with MPA in the
absence or presence of nucleoside triphosphates. Samples were prepared as indi-
cated under “Experimental Procedures.” IMPDH protein at a concentration of 50 g/ml
was incubated with ethanol vehicle (A), 1 mM GTP (B), or 2 mM ATP (C) for 15 min at room
temperature. Panels D–F show IMPDH protein after treatment with 2 M MPA for 15 min.
Protein was then incubated for an additional 15 min with water (D), 1 mM GTP (E), or 2 mM
ATP (F). The inserts represent higher magnifications of individual or dimeric tetamers (A)
or chains of tetramers (B, C, and E). Scale bar represents 100 nm for panels A—F, 42 nm for
inserts in panels B, C, and F, and 25 nm for inserts in panel A.
FIGURE 6. Schema of structural alterations of IMPDH induced by MPA and
nucleotides.
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intermediate bound to MPA. Recently, a similar mobility shift was
reported for the yeast family of IMD enzymes (16) and conclusively
shown to result from trapping of the covalently bound XMP interme-
diate in the presence of MPA. This shift was also reversible with the
removal of MPA. These data support the conclusion that the shift
results from a conformational change of the IMPDH protein, because
the magnitude of the shift considerably exceeds the molecular weight
increment of the enzyme-XMPMPA complex. We have now demon-
strated the same shift of IMPDH in a mononuclear cell lysate from a
patient receiving standard therapeutic doses ofMycophenolatemofeteil
(Fig. 1B). This alteration in gel mobility could provide a surrogate
marker for IMPDH inhibition in clinical studies of drugs that bind to the
NAD binding site.
We have here demonstrated a unique consequence of IMPDH inhi-
bition, the formation of large intracellular aggregates of protein that
result in distinct annular configurations in the cytoplasm. These aggre-
gates are formed in response to MPA, mizoribine, and VX-944, a new
IMPDH inhibitor, in all cell types tested. They do not appear to involve
any defined intracellular organelles either by immunocytochemical
costaining techniques or by electron microscopy. Despite extensive
investigation, we have not been able to identify any other interacting
proteins in this complex. Finally, treatment of highly purified IMPDH
proteinwithMPA ex vivo results in similar aggregation by both light and
negative staining electronmicroscopy. Thus, this striking configuration
of IMPDH appears to be a direct function of an alteration in protein
conformation. The ability of mizoribine to induce the ring-like aggre-
gation of IMPDH in intact cells, but not to induce the gel mobility shift,
implies that the trapping of XMP is not required for this effect.
The ability of guanosine to reverse the effects of IMPDH inhibition
has beenwell documented in numerous studies on the biologic sequelae
of IMPDH inhibition (5, 27, 28) and has been used to prove that guanine
nucleotide depletion is specifically responsible for the biologic effects of
IMPDH inhibitors. We have now shown, however, that guanine nucle-
otides also reverse the conformational change induced in IMPDH by
MPA treatment, both in vivo and in vitro.We have also shown that GTP
itself can bind to IMPDH protein at physiologic concentrations.
Although it is clear that GMP is a competitive inhibitor of IMPDH (29),
the direct binding of GTP to IMPDH has not previously been demon-
strated to our knowledge. We therefore hypothesize based on our
microscopy studies that the IMPDH tetramer forms linear arrays by
binding either ATP or GTP, putatively through the cystathione -syn-
thase domains. MPA, by causing conformational change in the protein
and by reducing intracellular GTP levels, induces the formation of high
molecular weight aggregates. The restoration of intracellularGTP levels
reverses MPA-induced aggregation and restores enzymatic activity.
The in vitro studies confirm that GTP not only reverses but also pre-
vents IMPDH aggregation.
Although the specific physicochemical basis for these conformational
changes has not been established, these studies indicate that the regu-
lation of IMPDH by GTP levels may be important in the multitude of
biologic effects of IMPDH inhibitors. Inhibition of IMPDH has been
found to inhibit T and B cell activation (30), induce the differentiation of
leukemic cell lines (31), cause apoptosis in hematopoietic and solid
tumor cell lines (27, 32), impair thematuration and function of dendritic
cells (33), and interfere with glycosylation, cell adhesion, and nitric
oxide synthesis (34, 35). The reversal of these important biologic effects
by increasing intracellular GTP levels may be in part attributable to
effects on IMPDH enzymatic activity and the restoration of de novo
guanine nucleotide biosynthesis.
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